雷帕霉素防治慢性移植肾肾病的新进展

New progress of Rapamycin in prevention and treatment of chronic allograft nephropathy

慢性移植肾肾病(CAN)为肾移植术后移植肾功能丧失的重要原因。环孢素(CsA)等神经碱钙蛋白抑制剂(C I)肾毒性为其中的重要因素之一。雷帕霉素(Rapa)为一种新型免疫抑制剂,与C I相比,具有全新的免疫抑制机制,可产生明确的抗增殖特性,而无肾毒性,对CAN的防治和肾移植术后患者的预后具有重要作用。该文就Rapa防治CAN的研究新进展作一综述。

Chronic allograft nephropathy（CAN） represents the primary cause of renal graft loss. Calcineurin inhibitor（CI） nephrotoxicity may be one of the most important pathogenetic factors in the develop- ment of this CAN. Rapamycin（Rapa）is a new immunosuppressive drug, its mechanism is different from that of CI and without nephrotoxicity. Moreover, Rapa has shown potent antiproliferative activity in different clinical and experimental models. The author reviewed relevant study of Rapa on preventing and treatment CAN.